REFERENCES
- Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. HIV RNA and CD4 cell count re-sponse to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13(6):F35–43.
- British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2001;2 (4):276–313.
- DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective stud-ies using a standardized data analysis plan. Antiviral Ther. 2000;5(1):41–48.
- Gulick RM, Hu XJ, Fiscus SA, et al. Randomised study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in Human Immunodeficiency Virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359. J Infect Dis. 2000;182:1375–1384.
- Hammer S, Squires K, Degruttola V, et al. Randomised trial of ABC, and nelfinavir in combination with efavirenz and adefovir dipivoxil as salvage therapy inpatients with viro-logic failure receiving indinavir. In: Program and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections; Chicago; Jan. 31-Feb. 4, 1999. Abstract 490.
- Shulman NS, Zolopa RA, Passaro DJ, et al. Efavirenz and adefovir dipivoxil based salvage therapy in highly treat-ment experienced patients: clinical and genotypic predic-tors of virologic response. J AIDS. 2000;23:221–226.
- Hammer SM, Vaida F, Bennett KK, et al. Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: a randomised trial. JAMA. 2002;288(2):239–241.
- Carmena J, Ricart C, Jordan M, Vicente R, Perez C, Alcaraz MJ, Leon P. Observational protease inhibitor sal-vage study, using efavirenz plus two new nucleoside re-verse transcriptase inhibitors. In: Program and abstracts of the Seventh Annual Meeting of the British HIV Association; April 2001; Brighton. Abstract P33.
- Albrecht MA, Bosch RJ, Liou SH, Katzenstein D. ACTG 364: efficacy of nelfinavir (NFV) and/or efavirenz (EFV) in combination with new NRTIs in nucleoside experienced subjects: week 144 results. In: Program and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle. Abstract 425–W.
- Nunez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish efavirenz vs nevirapine comparison): a random-ised, open label study in HIV infected naïve individuals. HIV Clin Trials. 2002 ; 3(3):186–194.
- Phillips AN, Pradier C, Lazzarin A, et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly anti-retroviral-experienced patients. AIDS. 200115: 2385–2395.
- Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in anti-retroviral-naïve patients: a cohort study. AIDS. 2002;16:53–61.
- Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. Virologic and immunologic response to regimens contain-ing nevirapine or efavirenz in combination with 2 nucleo-side analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis. 2002; 185(8):1062–1069.
- Keiser P, Nassar N, White C, Koen G, Moreno S. Cohort study shows treatment advantage across many risk factors for efavirenz vs. nevirapine-containing regimens in treat-ment-naïve HIV-1 infected individuals. In: Late breaker pro-gram of the Eighth European Conference on Clinical As-pects and Treatment of HIV Infection; 2001; Athens, Greece.
- Fischl M, Greenberg S, Clumeck N, et al. Ziagen combined with 3TC and ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral-therapy-naïve subjects (CNAA 3003). In: Program and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infec-tions; 1999; Chicago. Abstract 19.